{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T11:10:25Z","timestamp":1767006625044,"version":"build-2065373602"},"reference-count":73,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","interventional.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Interventional Cardiology Clinics"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.iccl.2022.07.002","type":"journal-article","created":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T23:28:57Z","timestamp":1665530937000},"page":"465-473","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Stent Thrombosis After Percutaneous Coronary Intervention"],"prefix":"10.1016","volume":"11","author":[{"given":"Alberto","family":"Polimeni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabato","family":"Sorrentino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Spaccarotella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Mongiardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolanda","family":"Sabatino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"De Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tommaso","family":"Gori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ciro","family":"Indolfi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.iccl.2022.07.002_bib1","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1161\/01.CIR.103.15.1967","article-title":"Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials","volume":"103","author":"Cutlip","year":"2001","journal-title":"Circulation"},{"issue":"42","key":"10.1016\/j.iccl.2022.07.002_bib2","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1093\/eurheartj\/ehx437","article-title":"Impact of design of coronary stents and length of dual antiplatelet therapies on ischaemic and bleeding events: a network meta-analysis of 64 randomized controlled trials and 102 735 patients","volume":"38","author":"D'Ascenzo","year":"2017","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.iccl.2022.07.002_bib3","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1056\/NEJMoa067484","article-title":"Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents","volume":"356","author":"Kastrati","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.iccl.2022.07.002_bib4","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s00395-012-0296-y","article-title":"Inhibition of miR-92a increases endothelial proliferation and migration in\u00a0vitro as well as reduces neointimal proliferation in\u00a0vivo after vascular injury","volume":"107","author":"Iaconetti","year":"2012","journal-title":"Basic Res Cardiol"},{"issue":"4","key":"10.1016\/j.iccl.2022.07.002_bib5","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/cvr\/cvv141","article-title":"Down-regulation of miR-23b induces phenotypic switching of vascular smooth muscle cells in\u00a0vitro and in\u00a0vivo","volume":"107","author":"Iaconetti","year":"2015","journal-title":"Cardiovasc Res"},{"issue":"12","key":"10.1016\/j.iccl.2022.07.002_bib6","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.jmb.2017.05.008","article-title":"miR-125a-5p modulates phenotypic switch of vascular smooth muscle cells by targeting ETS-1","volume":"429","author":"Gareri","year":"2017","journal-title":"J\u00a0Mol Biol"},{"issue":"1","key":"10.1016\/j.iccl.2022.07.002_bib7","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41598-017-19136-6","article-title":"Hindlimb ischemia impairs endothelial recovery and increases neointimal proliferation in the carotid artery","volume":"8","author":"Sorrentino","year":"2018","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.iccl.2022.07.002_bib8","doi-asserted-by":"crossref","first-page":"581 e581","DOI":"10.1016\/j.amjmed.2008.12.019","article-title":"Comprehensive meta-analysis on drug-eluting stents versus bare-metal stents during extended follow-up","volume":"122","author":"Roukoz","year":"2009","journal-title":"Am J Med"},{"issue":"11","key":"10.1016\/j.iccl.2022.07.002_bib9","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1161\/CIRCULATIONAHA.106.666800","article-title":"Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern","volume":"115","author":"Camenzind","year":"2007","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.iccl.2022.07.002_bib10","doi-asserted-by":"crossref","first-page":"e003785","DOI":"10.1161\/CIRCINTERVENTIONS.116.003785","article-title":"Failure mechanisms and neoatherosclerosis patterns in very late drug-eluting and bare-metal stent thrombosis","volume":"9","author":"Nakamura","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"issue":"10","key":"10.1016\/j.iccl.2022.07.002_bib11","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.amjcard.2018.07.041","article-title":"Dual antiplatelet therapy cessation and adverse events after drug-eluting stent implantation in patients at high risk for atherothrombosis (from the PARIS Registry)","volume":"122","author":"Sorrentino","year":"2018","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.iccl.2022.07.002_bib12","article-title":"Italian multicenter registry of bare metal stent use in modern percutaneous coronary intervention era (AMARCORD): a multicenter observational study","author":"Giannini","year":"2020","journal-title":"Catheter Cardiovasc Interv"},{"issue":"3","key":"10.1016\/j.iccl.2022.07.002_bib13","doi-asserted-by":"crossref","first-page":"H902","DOI":"10.1152\/ajpheart.00130.2003","article-title":"Effect of stent coating alone on in\u00a0vitro vascular smooth muscle cell proliferation and apoptosis","volume":"286","author":"Curcio","year":"2004","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"10.1016\/j.iccl.2022.07.002_bib14","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jacc.2006.03.042","article-title":"Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk","volume":"48","author":"Joner","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.iccl.2022.07.002_bib15","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1161\/01.CIR.0000116202.41966.D4","article-title":"Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?","volume":"109","author":"Virmani","year":"2004","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.iccl.2022.07.002_bib16","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1161\/01.CIR.0000041632.02514.14","article-title":"Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans","volume":"106","author":"Virmani","year":"2002","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.iccl.2022.07.002_bib17","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1161\/CIRCULATIONAHA.110.003210","article-title":"Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings","volume":"123","author":"Kolandaivelu","year":"2011","journal-title":"Circulation"},{"issue":"9710","key":"10.1016\/j.iccl.2022.07.002_bib18","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0140-6736(09)62127-9","article-title":"Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial","volume":"375","author":"Kedhi","year":"2010","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.iccl.2022.07.002_bib19","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jcin.2013.06.015","article-title":"Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients","volume":"6","author":"Tada","year":"2013","journal-title":"JACC Cardiovasc Interv"},{"issue":"17","key":"10.1016\/j.iccl.2022.07.002_bib20","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/eurheartj\/eht570","article-title":"Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis","volume":"35","author":"Kang","year":"2014","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.iccl.2022.07.002_bib21","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1001\/jama.2012.10065","article-title":"Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial","volume":"308","author":"Raber","year":"2012","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.iccl.2022.07.002_bib22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jcin.2013.07.012","volume":"7","author":"Sabate","year":"2014","journal-title":"JACC Cardiovasc Interv"},{"issue":"9","key":"10.1016\/j.iccl.2022.07.002_bib23","doi-asserted-by":"crossref","first-page":"e007705","DOI":"10.1161\/CIRCINTERVENTIONS.118.007705","article-title":"Does large vessel size justify use of bare-metal stents in primary percutaneous coronary intervention?","volume":"12","author":"Costa","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"issue":"11","key":"10.1016\/j.iccl.2022.07.002_bib24","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1055\/s-0038-1673687","article-title":"Determinants of significant out-of-hospital bleeding in patients undergoing percutaneous coronary intervention","volume":"118","author":"Sorrentino","year":"2018","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.iccl.2022.07.002_bib25","doi-asserted-by":"crossref","first-page":"e008226","DOI":"10.1161\/CIRCINTERVENTIONS.119.008226","article-title":"Bleeding risk, dual antiplatelet therapy cessation, and adverse events after percutaneous coronary intervention: the PARIS registry","volume":"13","author":"Sorrentino","year":"2020","journal-title":"Circ Cardiovasc Interv"},{"issue":"4","key":"10.1016\/j.iccl.2022.07.002_bib26","doi-asserted-by":"crossref","first-page":"e007133","DOI":"10.1161\/CIRCINTERVENTIONS.118.007133","article-title":"Influence of baseline anemia on dual antiplatelet therapy cessation and risk of adverse events after percutaneous coronary intervention","volume":"12","author":"Faggioni","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"issue":"6","key":"10.1016\/j.iccl.2022.07.002_bib27","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.amjcard.2017.06.016","article-title":"Causes, timing, and impact of dual antiplatelet therapy interruption for surgery (from the patterns of non-adherence to anti-platelet regimens in stented patients registry)","volume":"120","author":"Schoos","year":"2017","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.iccl.2022.07.002_bib28","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jcin.2015.11.015","article-title":"Is bare-metal stent implantation still justifiable in high bleeding risk patients undergoing percutaneous coronary intervention?: a pre-specified analysis from the zeus trial","volume":"9","author":"Ariotti","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"issue":"21","key":"10.1016\/j.iccl.2022.07.002_bib29","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1056\/NEJMoa1503943","article-title":"Polymer-free drug-coated coronary stents in patients at high bleeding risk","volume":"373","author":"Urban","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.iccl.2022.07.002_bib30","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.jacc.2014.11.053","article-title":"Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates","volume":"65","author":"Valgimigli","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2022.07.002_bib31","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ahj.2018.08.004","article-title":"Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention","volume":"205","author":"Mauri","year":"2018","journal-title":"Am Heart J"},{"key":"10.1016\/j.iccl.2022.07.002_bib32","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ahj.2019.04.017","article-title":"Rationale and design of the Onyx ONE global randomized trial: a randomized controlled trial of high-bleeding risk patients after stent placement with 1month of dual antiplatelet therapy","volume":"214","author":"Kedhi","year":"2019","journal-title":"Am Heart J"},{"key":"10.1016\/j.iccl.2022.07.002_bib33","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ahj.2018.10.009","article-title":"Design and rationale of the management of high bleeding risk patients post bioresorbable polymer coated stent implantation with an abbreviated versus standard DAPT regimen (MASTER DAPT) study","volume":"209","author":"Frigoli","year":"2019","journal-title":"Am Heart J"},{"issue":"11","key":"10.1016\/j.iccl.2022.07.002_bib34","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1161\/CIRCULATIONAHA.119.041619","article-title":"Long-term safety and efficacy of durable polymer cobalt-chromium everolimus-eluting stents in patients at high bleeding risk: a patient-level stratified analysis from four postapproval studies","volume":"141","author":"Sorrentino","year":"2020","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.iccl.2022.07.002_bib35","doi-asserted-by":"crossref","first-page":"e99648","DOI":"10.1371\/journal.pone.0099648","article-title":"Safety and efficacy of biodegradable drug-eluting vs. bare metal stents: a meta-analysis from randomized trials","volume":"9","author":"Yin","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.iccl.2022.07.002_bib36","doi-asserted-by":"crossref","first-page":"224","DOI":"10.4244\/EIJ-D-18-00024","article-title":"Outcomes of patients treated with ultrathin strut biodegradable-polymer sirolimus-eluting stents versus fluoropolymer-based everolimus-eluting stents. A meta-analysis of randomized trials","volume":"14","author":"Cassese","year":"2018","journal-title":"EuroIntervention"},{"issue":"1","key":"10.1016\/j.iccl.2022.07.002_bib37","doi-asserted-by":"crossref","first-page":"14997","DOI":"10.1038\/s41598-017-14247-6","article-title":"A\u00a0comparison of the main outcomes from BP-BES and DP-DES at five years of follow-up: a systematic review and meta-analysis","volume":"7","author":"Lu","year":"2017","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.iccl.2022.07.002_bib38","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/CIRCULATIONAHA.114.013520","article-title":"Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitats Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial","volume":"131","author":"Kaiser","year":"2015","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.iccl.2022.07.002_bib39","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.jcin.2017.02.029","volume":"10","author":"Vlachojannis","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"issue":"4","key":"10.1016\/j.iccl.2022.07.002_bib40","doi-asserted-by":"crossref","first-page":"e002372","DOI":"10.1161\/CIRCINTERVENTIONS.114.002372","article-title":"Efficacy and safety of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent: the EVOLVE II randomized trial","volume":"8","author":"Kereiakes","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"issue":"10105","key":"10.1016\/j.iccl.2022.07.002_bib41","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(17)32249-3","article-title":"Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial","volume":"390","author":"Kandzari","year":"2017","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.iccl.2022.07.002_bib42","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1161\/01.CIR.98.20.2126","article-title":"Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS)","volume":"98","author":"Urban","year":"1998","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.iccl.2022.07.002_bib43","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1093\/eurheartj\/ehi405","article-title":"Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating","volume":"26","author":"Hausleiter","year":"2005","journal-title":"Eur Heart J"},{"issue":"10119","key":"10.1016\/j.iccl.2022.07.002_bib44","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0140-6736(17)33103-3","article-title":"A\u00a0sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial","volume":"391","author":"de Winter","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.iccl.2022.07.002_bib45","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12872-017-0603-5","article-title":"Efficacy and safety of polymer-free stent versus polymer-permanent drug-eluting stent in patients with acute coronary syndrome: a meta-analysis of randomized control trials","volume":"17","author":"Gao","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"issue":"16","key":"10.1016\/j.iccl.2022.07.002_bib46","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.4244\/EIJ-D-17-00728","article-title":"Acute thrombogenicity of fluoropolymer-coated versus biodegradable and polymer free stents","volume":"14","author":"Torii","year":"2018","journal-title":"EuroIntervention"},{"issue":"2","key":"10.1016\/j.iccl.2022.07.002_bib47","doi-asserted-by":"crossref","first-page":"e007311","DOI":"10.1161\/CIRCINTERVENTIONS.118.007311","article-title":"Safety and efficacy of polymer-free drug-eluting stents","volume":"12","author":"Chiarito","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"issue":"12","key":"10.1016\/j.iccl.2022.07.002_bib48","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nrcardio.2016.151","article-title":"Bioresorbable vascular scaffolds - basic concepts and clinical outcome","volume":"13","author":"Indolfi","year":"2016","journal-title":"Nat Rev Cardiol"},{"issue":"5","key":"10.1016\/j.iccl.2022.07.002_bib49","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1161\/CIRCULATIONAHA.117.031843","article-title":"Three-year outcomes with the absorb bioresorbable scaffold: individual-patient-data meta-analysis from the ABSORB randomized trials","volume":"137","author":"Ali","year":"2018","journal-title":"Circulation"},{"issue":"10096","key":"10.1016\/j.iccl.2022.07.002_bib50","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(17)31470-8","article-title":"2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy","volume":"390","author":"Ali","year":"2017","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.iccl.2022.07.002_bib51","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1016\/j.jacc.2017.10.010","article-title":"3-year clinical outcomes with everolimus-eluting bioresorbable coronary scaffolds: the ABSORB III trial","volume":"70","author":"Kereiakes","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"10025","key":"10.1016\/j.iccl.2022.07.002_bib52","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(15)01039-9","article-title":"1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis","volume":"387","author":"Stone","year":"2016","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.iccl.2022.07.002_bib53","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.4244\/EIJ-D-17-00873","article-title":"Four-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II Trial)","volume":"13","author":"Chevalier","year":"2018","journal-title":"EuroIntervention"},{"issue":"10059","key":"10.1016\/j.iccl.2022.07.002_bib54","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1016\/S0140-6736(16)32050-5","article-title":"Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial","volume":"388","author":"Serruys","year":"2016","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.iccl.2022.07.002_bib55","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1056\/NEJMoa1614954","article-title":"Bioresorbable scaffolds versus metallic stents in routine PCI","volume":"376","author":"Wykrzykowska","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.iccl.2022.07.002_bib56","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12872-017-0586-2","article-title":"Long-term outcome of bioresorbable vascular scaffolds for the treatment of coronary artery disease: a meta-analysis of RCTs","volume":"17","author":"Polimeni","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"issue":"25","key":"10.1016\/j.iccl.2022.07.002_bib57","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1016\/j.jacc.2017.04.011","article-title":"Everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents","volume":"69","author":"Sorrentino","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.iccl.2022.07.002_bib58","first-page":"32","article-title":"Early, late and very late incidence of bioresorbable scaffold thrombosis: a systematic review and meta-analysis of randomized clinical trials and observational studies","volume":"65","author":"Collet","year":"2017","journal-title":"Minerva Cardioangiol"},{"key":"10.1016\/j.iccl.2022.07.002_bib59","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.ijcard.2016.07.101","article-title":"Safety and efficacy of everolimus-eluting bioresorbable vascular scaffolds versus durable polymer everolimus-eluting metallic stents assessed at 1-year follow-up: a systematic review and meta-analysis of studies","volume":"221","author":"Mukete","year":"2016","journal-title":"Int J Cardiol"},{"issue":"1","key":"10.1016\/j.iccl.2022.07.002_bib60","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12872-019-1042-2","article-title":"Bioresorbable vascular scaffolds for percutaneous treatment of chronic total coronary occlusions: a meta-analysis","volume":"19","author":"Polimeni","year":"2019","journal-title":"BMC Cardiovasc Disord"},{"issue":"18","key":"10.1016\/j.iccl.2022.07.002_bib61","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.jcin.2017.07.034","article-title":"Incidence, clinical presentation, and predictors of clinical restenosis in coronary bioresorbable scaffolds","volume":"10","author":"Polimeni","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"issue":"9","key":"10.1016\/j.iccl.2022.07.002_bib62","doi-asserted-by":"crossref","first-page":"e1011","DOI":"10.4244\/EIJ-D-17-00410","article-title":"Characteristics and outcome of patients with complex coronary lesions treated with bioresorbable scaffolds: three-year follow-up in a cohort of consecutive patients","volume":"14","author":"Anadol","year":"2018","journal-title":"EuroIntervention"},{"issue":"1\u20132","key":"10.1016\/j.iccl.2022.07.002_bib63","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3233\/CH-189101","article-title":"Bioresorbable everolimus-eluting vascular scaffold for patients presenting with non STelevation-acute coronary syndrome: a three-years follow-up1","volume":"69","author":"Anadol","year":"2018","journal-title":"Clin Hemorheol Microcirc"},{"issue":"1","key":"10.1016\/j.iccl.2022.07.002_bib64","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12872-018-0811-7","article-title":"Three-years outcomes of diabetic patients treated with coronary bioresorbable scaffolds","volume":"18","author":"Anadol","year":"2018","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.iccl.2022.07.002_bib65","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ijcard.2018.04.081","article-title":"Predictors of bioresorbable scaffold failure in STEMI patients at 3years follow-up","volume":"268","author":"Polimeni","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.iccl.2022.07.002_bib66","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12872-015-0163-5","article-title":"The duration of balloon inflation affects the luminal diameter of coronary segments after bioresorbable vascular scaffolds deployment","volume":"15","author":"Sorrentino","year":"2015","journal-title":"BMC Cardiovasc Disord"},{"issue":"1","key":"10.1016\/j.iccl.2022.07.002_bib67","first-page":"93","article-title":"Procedural predictors for bioresorbable vascular scaffold thrombosis: analysis of the individual components of the \"PSP\" technique","volume":"8","author":"Dimitriadis","year":"2019","journal-title":"J\u00a0Clin Med"},{"issue":"23","key":"10.1016\/j.iccl.2022.07.002_bib68","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1016\/j.jcin.2017.08.020","article-title":"Characteristics, predictors, and mechanisms of thrombosis in coronary bioresorbable scaffolds: differences between early and late events","volume":"10","author":"Gori","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"issue":"2","key":"10.1016\/j.iccl.2022.07.002_bib69","first-page":"117","article-title":"Bioresorbable vascular scaffold: a step back thinking of the future","volume":"14","author":"Polimeni","year":"2018","journal-title":"Postepy Kardiol Interwencyjnej"},{"issue":"4","key":"10.1016\/j.iccl.2022.07.002_bib70","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/s41569-018-0118-5","article-title":"Predictors of stent thrombosis and their implications for clinical practice","volume":"16","author":"Gori","year":"2019","journal-title":"Nat Rev Cardiol"},{"issue":"5","key":"10.1016\/j.iccl.2022.07.002_bib71","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1253\/circj.CJ-19-1184","article-title":"Long-term outcomes of absorb bioresorbable vascular scaffold vs. everolimus-eluting metallic stent- a randomized comparison through 5 years in Japan","volume":"84","author":"Kozuma","year":"2020","journal-title":"Circ J"},{"issue":"12","key":"10.1016\/j.iccl.2022.07.002_bib72","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jamacardio.2019.4101","article-title":"Time-varying outcomes with the absorb bioresorbable vascular scaffold during 5-year follow-up: a systematic meta-analysis and individual patient data pooled study","volume":"4","author":"Stone","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"35","key":"10.1016\/j.iccl.2022.07.002_bib73","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1093\/eurheartj\/ehw196","article-title":"Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with\u00a0de novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial","volume":"37","author":"Haude","year":"2016","journal-title":"Eur Heart J"}],"container-title":["Interventional Cardiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211745822000529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211745822000529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T18:01:52Z","timestamp":1761933712000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211745822000529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":73,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S2211745822000529"],"URL":"https:\/\/doi.org\/10.1016\/j.iccl.2022.07.002","relation":{},"ISSN":["2211-7458"],"issn-type":[{"type":"print","value":"2211-7458"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stent Thrombosis After Percutaneous Coronary Intervention","name":"articletitle","label":"Article Title"},{"value":"Interventional Cardiology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iccl.2022.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}